Inhibrx Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Inhibrx Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $-40 of operating cash. Lower than 97% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$-40Over the last 3 years, every $100 of reported profit came with $-40 of operating cash.
Lower than 97% of Healthcare companies in United States.
Self-Funding Ratio
-71.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 78% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -0% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-0% / +780%In 3 years sales changed by -0% while total assets changed by +780%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-55.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 75% of Healthcare companies in United States.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Lower than 65% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Inhibrx Biosciences, Inc. made a loss over the last year. Inhibrx Biosciences, Inc. owes $1.34 for every $1 it owns. Inhibrx Biosciences, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossInhibrx Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-26.98Inhibrx Biosciences, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1.4 BThe total market value of all of Inhibrx Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 68% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeInhibrx Biosciences, Inc.'s net worth is negative ($53 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-1773.6%Inhibrx Biosciences, Inc. lost 1773.6% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
1.34×Inhibrx Biosciences, Inc. owes $1.34 for every $1 it owns, so it owes more than it owns, higher than 92% of Healthcare companies in United States.
Dividend yield
NoneInhibrx Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+550%Revenue rose 550% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Profit growth
LossInhibrx Biosciences, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-10773.5%Inhibrx Biosciences, Inc. lost $10773 for every $100 of revenue.
Interest cover
Not coveredInhibrx Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashInhibrx Biosciences, Inc. held $17 M more cash than debt (net cash) at Dec 2025.
Questions
What is Inhibrx Biosciences, Inc.'s return on equity?
Inhibrx Biosciences, Inc. lost 1773.6% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does Inhibrx Biosciences, Inc. owe compared with what it owns?
Inhibrx Biosciences, Inc. owes $1.34 for every $1 it owns, so it owes more than it owns, higher than 92% of Healthcare companies in United States.
Does Inhibrx Biosciences, Inc. pay a dividend?
No. Inhibrx Biosciences, Inc. does not currently pay a dividend.
Is Inhibrx Biosciences, Inc.'s revenue growing?
Revenue rose 550% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.